EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer

Sailaja Kamaraju, Amy M Fowler, Sergey Tarima, Lubna N Chaudhary, Mark E Burkard, Thomas Giever, Yee C Cheng, Amanda Parkes, Carol A Lange, Michele Pipp-Dahm, Robert Hegeman, Nauman Siddiqui und 12 weitere

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2024.11.019 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Sailaja Kamaraju und 23 weiteren Autor:innen. Beteiligte Einrichtung: Froedtert & Medical College of Wisconsin, Cancer Center, Milwaukee, WI, 53226. Electronic address: skamaraju@mcw.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Fulvestrant, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes. METHODS: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.1 criteria, and optional 18F-fluorofuranylnorprogesterone (18F-FFNP) PET/CT imaging. RESULTS: Consented subjects received standard-dose fulvestrant plus onapristone 50 mg orally, twice daily, until disease progression, or unacceptable toxicity. The study enrolled 11 women from 2 sites within the Wisconsin Oncology Network from November 2021 through March 2023. Mean age of the subjects was 58.5 years. Other than grade 1 toxicities, the treatment was well tolerated. None of the 11 subjects met RECIST 1.1 definition of response. The median time to progression was 63 days. A total of 4 of 11 patients had stable disease as best response and 2 of them were on treatment for 5.5 and 7.7 months. Two of the 11 subjects underwent functional imaging with 18F-FFNP PET/CT before and 10 or 14 days after starting treatment. For both subjects, tumor uptake of 18F-FFNP was stable or increased in all target lesions while 18F-FFNP uptake in the uterus, a normal PgR-rich internal control organ, was decreased. CONCLUSION: The study regimen was well-tolerated with no significant toxicities. Future studies may evaluate antiprogestins with various combinations such as targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFulvestrantAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenAgedReceptors, ProgesteroneAdultPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

AntiprogestinsCDK4/6 inhibitorsHormone receptor positiveMetastatic breast cancerNovel treatments

Substanzen

FulvestrantErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Froedtert & Medical College of Wisconsin, Cancer Center, Milwaukee, WI, 53226. Electronic address: skamaraju@mcw.edu.
  • Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792-3252.
  • Froedtert & Medical College of Wisconsin, Cancer Center, Milwaukee, WI, 53226; Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 53226.
  • Froedtert & Medical College of Wisconsin, Cancer Center, Milwaukee, WI, 53226.
  • UI Holden Comprehensive Cancer Center, Iowa City, IA 52242.
  • Department of Hematology-Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792.

Förderung

  • NCI NIH HHS

Zitieren

APA

Kamaraju, S., Fowler, A. M., Tarima, S., Chaudhary, L. N., Burkard, M. E., Giever, T., Cheng, Y. C., Parkes, A., Lange, C. A., Pipp-Dahm, M., Hegeman, R., Siddiqui, N., Stella, A., Rajguru, S., Twaroski, K., Zurbriggen, L., Jorns, J. M., Rui, H., Keigley, Q. J., …, & Wisinski, K. (2025). A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.11.019

Vancouver

Kamaraju S, Fowler AM, Tarima S, Chaudhary LN, Burkard ME, Giever T, et al. A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.11.019

BibTeX
@article{Kamaraju2025,
  author = {Kamaraju, Sailaja and Fowler, Amy M and Tarima, Sergey and Chaudhary, Lubna N and Burkard, Mark E and Giever, Thomas and Cheng, Yee C and Parkes, Amanda and Lange, Carol A and Pipp-Dahm, Michele and Hegeman, Robert and Siddiqui, Nauman and Stella, Amy and Rajguru, Saurabh and Twaroski, Kyleigh and Zurbriggen, Luke and Jorns, Julie M and Rui, Hallgeir and Keigley, Quinton J and Perlman, Scott B and Salem, Kelley and Bradshaw, Tyler J and Sahmoud, Tarek and Wisinski, Kari},
  title = {A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2024.11.019}
}
Kostenlos starten →